NovaBay Pharmaceuticals has initiated a Phase II trial of a compound to prevent urinary catheter blockage and encrustation (UCBE), a major factor behind urinary tract infections.
The multi-centre, randomised, double-blind proof-of-concept trial will compare the use of a catheter irrigation solution containing the compound, NVC-422, against the use of a saline irrigation, the commonly used option for UCBE treatment.
Go deeper with GlobalData
The study will involve subjects with a history of chronic episodes of UCBE.
The trial design is a crossover study in which the patient serves as his or her own control, where patients will receive either NVC-422 or saline solution followed by a treatment with the other solution.
The primary outcome measures include catheter patency following treatment, while secondary outcome measures include incidence of catheter blockage requiring early removal, assessment of biofilm of the catheter, and assessment of encrustation of catheter.
NovaBay expects the trial to be completed in the third quarter of 2011 with results available in the fourth quarter. The company has plans to initiate a Phase III registration study for UCBE in 2012.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
